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P U B L I S H E D B Y E L S E V I E R I N C .LettersRe-Examination of the
Antithrombotic Regimen
in the STEMI-RADIAL TrialIn the STEMI-RADIAL (ST Elevation Myocardial
Infarction treated by RADIAL or femoral approach)
trial (1), the primary endpoint of the cumulative
incidence of major bleeding and vascular access site
complications at 30 days was lower with transradial
intervention than with transfemoral intervention
(1.4% vs. 7.2%, p ¼ 0.0001). There was no difference
in death, myocardial infarction, and stroke. However,
this trial included suboptimal antithrombotic regi-
mens, including high doses of heparin and a high
percentage of patients treated with glycoprotein
IIb/IIIa inhibitors. In patients with ST-segment
elevation myocardial infarction (STEMI) being re-
ferred for primary percutaneous coronary interven-
tion, the American College of Cardiology Foundation/
American Heart Association guideline recommends a
bolus of 50 to 70 IU/kg to achieve an activated
clotting time of 200 to 250 s when treatment with a
glycoprotein IIb/IIIa inhibitor is planned and 70 to
100 IU/kg to achieve an activated clotting time of 250
to 300 s (as measured by the HemoTec device, Hemo-
Tec Inc., Englewood, Colorado) when no treatment
with a glycoprotein IIb/IIIa inhibitor is planned (2).
Doses of heparin in excess of this have not been
associated with improved pre-procedural patency or
post-procedural outcomes. Patients who underwent
transfemoral intervention received an average dose of
heparin of 105 IU/kg, despite nearly half of the patients
being treated with glycoprotein IIb/IIIa inhibitors.
Bivalirudin, a direct thrombin inhibitor shown to
decrease bleeding and improve outcomes compared
with heparin and glycoprotein IIb/IIIa inhibitors in
patients undergoing an invasive strategy, was not used
in the STEMI-RADIAL trial (3). The HORIZONS-AMI
(Harmonizing Outcomes With Revascularization and
Stents in Acute Myocardial Infarction) trial, which
compared patients with STEMI randomized to treat-
ment with heparin plus glycoprotein IIb/IIIa inhibitors
or bivalirudin, reported a 34% reduction inmortality in
patients treated with bivalirudin (p¼0.047), driven by
a reduction in major bleeding of 40% (p < 0.001).The applications of the trial ﬁndings are suspect
given the suboptimal antithrombotic regimens and
the liberal use of potent parenteral antiplatelet agents
(4). This is an important consideration especially for
patients with acute coronary syndrome, in whom the
negative implications of major bleeding are even
greater. Ultimately, a trial comparing transradial with
transfemoral intervention in patients treated with
bivalirudin, with potent antiplatelet therapy, and
without adjunctive glycoprotein IIb/IIIa inhibitors as
well as possibly incorporating ultrasound guidance
for vascular access is needed (5,6).*Michael S. Lee, MD
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Antithrombotic Regimen in the
STEMI-RADIAL TrialWe are pleased to address Dr. Lee’s comments on
the results of the STEMI-RADIAL (ST Elevation
Myocardial Infarction treated by RADIAL or femoral
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1297approach) trial published in the Journal (1). First, this
letter has already been published twice with almost
identical content (2,3). Second, responses to Dr. Lee’s
comments are already included in our report. In
brief, Dr. Lee contends that unfractionated heparin
was not used in accordance with guideline recom-
mendations and that bivalirudin should have been
used instead. As explained in the Methods section
and in accordance with the most recent guidelines,
an initial unfractionated heparin bolus dose of 70
IU/kg or a maximum dose of 5,000 IU was given
(sometimes in the ambulance). Further adjustments
were made according to the activated clotting time
results, leading to a mean total dose of 104  32
IU/kg with no difference between groups. Platelet
glycoprotein IIb/IIIa receptor inhibitors were used in
45% of the cases when required during percutaneous
coronary intervention as judged by the operators
(provisional use). This rate is similar to the current
experience with ST-segment elevation myocardial
infarction (STEMI) in the United States (4,5). As
explained in the Study Limitations section, bivalir-
udin was not used because it is not available in the
Czech Republic. Furthermore, the recent results of
the HEAT-PPCI (How Effective Are Antithrombotic
Therapies in Primary Percutaneous Coronary Inter-
vention) trial cast serious doubt on the claimed
overwhelming superiority of bivalirudin over hepa-
rin in patients with STEMI undergoing primary
percutaneous coronary intervention (6). Further
studies such as SAFARI-STEMI (The Safety and Efﬁ-
cacy of Femoral Access Versus Radial for Primary
Percutaneous Coronary Intervention in ST-Elevation
Myocardial Infarction), which will evaluate the ben-
eﬁts of a radial compared with a femoral approach in
patients with STEMI on a background of bivalirudin,
and EASY-B2B (EArly Discharge After TransradialStenting of CoronarY Arteries in High-Risk Patients
of Bleeding), which will compare bivalirudin with
heparin monotherapy in all comers at high risk for
bleeding undergoing transradial percutaneous coro-
nary intervention, should provide new insight into
the interaction between anticoagulation and access
site in the near future.*Ivo Bernat, MD, PhD
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